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Abstract
Introduction: Concomitant use of ledipasvir and boosted protease inhibitors (PIs) may increase the risk of tenofovir
(TDF) nephrotoxicity, since both these drugs increase TDF levels. Our aim was to evaluate glomerular filtration rate
(eGFR) evolution during HCV treatment with sofosbuvir/ledipasvir (SOF/LDV) in HCV/HIV coinfected patients,
according to their antiretroviral treatment (ARV).
Methods: Observational prospective study of HCV/HIV coinfected patients treated with SOF/LDV. eGFR evolution was
evaluated during and 12 weeks after HCV treatment. Patients were categorized in three groups based on ARV regimen:
non TDF, non-boosted TDF and TDF + boosted PI.
Results: We included 273 patients: 145 were receiving a non-TDF regimen, 78 a non-boosted TDF scheme and 50
were receiving TDF + boosted PI. We observed a statistically significant decrease in eGFR during treatment in all groups
(non TDF p = 0.03, 95%CI [0.23–3.86], non-boosted TDF p < 0.01, 95%CI [3.36–7.44], TDF + PI p = 0.01, 95%CI [1.09–7.53]).
The decrease was more pronounced in those receiving unboosted TDF (− 5.40 ml/min/1.73m2), but differences in eGFR
decrease between the three groups were small and not statistically different (p = 0.06). eGFR decrease was greater in
patients treated for 24 weeks (p = 0.009) and in cirrhotic patients (p = 0.036). At the end of follow up a recovery of eGFR
was observed in all groups.
Conclusion: We observed a significant decrease in eGFR during treatment in all study groups, that was small
and reversible after SOF/LDV discontinuation. TDF was not associated with an increase in renal toxicity.
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Background
According to the World Health Organization (WHO),
2–15% of the people infected by the human immuno-
deficiency virus (HIV) are coinfected with hepatitis C
virus (HCV), and this percentage goes up to 90% in
those who acquired the infection through intravenous
drug use [1]. Liver disease is currently one of the leading
causes of morbidity and mortality in HIV infected
people [2, 3] and HIV coinfected patients seem to have a
faster progression to cirrhosis, a higher rate of liver de-
compensation and liver death and a lower response to
HCV therapy [4–6] . However, HCV treatment has been
shown to decrease the risk of negative outcomes even in
co-infected patients [7].
With the advent of direct acting antivirals (DAAs), the
sustained virologic response (SVR) rates in mono and
HIV co-infected patients are similar. With these agents,
high cure rates are achieved in the co-infected popula-
tion, with excellent tolerability and convenient posology
[8, 9]. HIV specialists have always been aware of the im-
portance of surveilling and managing drug-drug interac-
tions (DDIs) between antiretroviral medication (ARV)
and other co-medication. DDIs are currently one of the
problems in the use of DAAs in co-infected patients [8–
10]. Clinicians are advised to check possible DDIs be-
tween the HCV DAAs and other chronic medication,
using up to date resources such as the one found at
http://www.hep-druginteractions.org [8].
The association in a single tablet of sofosbuvir (SOF),
a nucleotide NS5B polymerase inhibitor, and ledipasvir
(LDV), an inhibitor of nonstructural protein 5A (NS5A),
is one of the possible treatment options for HCV geno-
types 1 and 4, and has shown impressive results in
co-infected patients both in clinical trials [11] and in real
life cohorts [12]. This combination has few interactions
with ARV and can be used with nonnucleoside reverse
transcriptase inhibitors (NNRTIs), integrase inhibitors or
ritonavir-boosted HIV protease inhibitors (PIs), exclud-
ing tipranavir [8, 10].
However, recent studies have raised concerns regard-
ing the interaction between LDV and tenofovir (TDF).
Although the mechanism is not completely understood,
it is thought that LDV increases TDF levels through the
inhibition of P-glycoprotein (P-gp) and breast cancer re-
sistance protein (BCRP) [13]. Moreover, it has been
shown that TDF exposure is even greater (30–60%)
when SOF/LDV was co-administered with a boosted PI
[14]. As administration of TDF with a boosted PI already
increases TDF by 20–30%, most authors and guidelines
recommend changing ARV or DAA therapy; if, however,
this triple combination must be used, renal function
should be closely monitored [13, 15–17]. In those with a
glomerular filtration rate < 60 mL/min, these drugs
should be avoided [13, 15–17].
The aim of our study was to evaluate the effect of the
combination SOF/LDV in the eGFR in HCV/HIV pa-
tients who were receiving TDF as part of their antiretro-
viral therapy, and to analyze the added risk of the
concomitant use of a boosted PI.
Methods
This was a single center observational prospective study
regarding all HCV/HIV patients treated with DAAs in
our department. Data on baseline characteristics,
co-morbidities, medication and evolution during HCV
treatment was collected in a database that was previ-
ously approved by the hospital’s ethical commission, as
well as by the National Data Protection Commission. In-
formed consent was obtained for all patients.
We analyzed the data of those patients who were
treated with SOF/LDV for HCV and who had completed
at least 12 weeks of follow up after treatment, from
February 2015 to July 2017; patients who did not
complete 12 weeks of follow up after treatment were ex-
cluded (death or abandonment) as well as patients with
incomplete records. Patients were categorized in three
groups according to their ARV regimen: (1) non TDF
containing regimen (non TDF), (2) TDF without a
boosted PI (non-boosted TDF) or (3) TDF with a ritona-
vir boosted PI (boosted TDF). Evolution of estimated
glomerular filtration rate (eGFR) during and after HCV
treatment was compared amongst the three groups.
eGFR was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) formula.
Statistical analysis was performed using Statistical
Package for the Social Sciences (SPSS®) software, version
23. Paired t- test was used for comparing baseline and
end of treatment (EOT) mean eGFR evolution in each
group, likelihood ratio was used for categorical variable
analysis, ANOVA for analysis of mean difference within
the 3 groups and Wilcoxon signed-rank test to evaluate
the impact of cirrhosis in the eGFR. P-value < 0.05 was
defined as statistically significant.
All patients in our cohort were evaluated for liver fi-
brosis using transient hepatic elastography (Fibroscan®)
and, in some cases, liver biopsy. Patients with an hepatic
elastrography value ≥12.5 KPa were considered cirrhotic.
Results
From February 2015 until July 2017, 333 HCV/HIV
coinfected patients were treated for chronic HCV in-
fection in our department. Of these, 273 (81.9%) were
prescribed the combination SOF/LDV for 12–24 weeks
and completed 12 weeks of follow up. We excluded
19 patients from our analysis (three died during HCV
treatment, three were lost to follow up and 13 had
incomplete records).
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All the 273 HCV/HIV patients were receiving antiretro-
viral medication: 53.1% (n = 145) received a non-TDF regi-
men, 28.6% (n = 78) used an unboosted TDF scheme and
TDF plus boosted PI was administered in 18.3% (n = 50).
Efavirenz was the most used third agent in both the
non-TDF and unboosted-TDF groups (n = 50, 34,5% and
n = 52, 66,7%, respectively); other drugs less used included
rilpivirine (n = 2, 1,4% and n = 6, 7,7% respectively) and
dolutegravir (n = 10, 6,9% and n = 1, 1,3%, respectively).
Regarding the TDF + PI group, the most frequently used
boosted PI was darunavir (n = 27, 54%), followed by ataza-
navir (n = 14, 28%) and finally lopinavir (n = 9, 18%); rito-
navir was the booster used in all cases.
The baseline characteristics of the three groups
(non-TDF, non-boosted TDF and with TDF + PI) are
shown in Table 1. Almost all patients had undetectable
HIV RNA (n = 258, 94.5%) and the mean CD4 cell count
was 650/mm3 (±338/mm3).
The mean baseline eGFR was 100.9 ml/min/1.73m2
(±16.3) in the non TDF group, 104.1 ml/min/1.73m2
(±11.3) in non-boosted TDF and 98.2 ml/min/1.73m2 (±
11.8) in the TDF + boosted PI group. In all groups, we
observed a decrease in eGFR during treatment, as is
shown in Fig. 1.
The decrease of eGFR between the baseline and the
end of treatment (EOT) was statistically significant in all
groups (non TDF p = 0.03, 95%CI [0.23–3.86],
non-boosted TDF p < 0.01, 95%CI [3.36–7.44], TDF + PI
p = 0.01, 95%CI [1.09–7.53]). The decrease was more
pronounced in those receiving unboosted TDF (mean
difference 5.40 ml/min/1.73m2; 95%CI [(− 7.44) -(−
3.37)]), than in those receiving either TDF + boosted PI
(mean difference 4.31 ml/min/1.73m2; 95%CI [(− 7.53)
-(− 1.09)] or non TDF regimens (mean difference
2.02 ml/min/1.73m2; 95%CI [(− 3.84) -(− 0.02)]). Differ-
ences in eGFR decrease between the three groups were
small and were not statistically different (p = 0.06).
(Table 2).
At the end of follow up a recovery of eGFR was ob-
served in all groups (Fig. 1).
The evolution of eGFR was similar between those
who were treated for 12 weeks (n = 188) to those
treated for 24 weeks (n = 85). However, there was a
steeper decrease in eGFR in those who receiving a lon-
ger treatment course: mean change was − 2.1 95%CI
[(− 3.43) -(− 7.96)] in those treated for 12 weeks and
− 6.3 ml/min/1.73m2 95%CI [(− 9.08) -(− 3.47)] in
those treated for 24 weeks (p = 0.009). There was a
statistical significant difference in mean eGFR de-
crease amongst the three ARV groups in those treated
for 24 weeks (p = 0.026), but not in those who were
treated for 12 weeks (p = 0.89). Of note, there was a higher
proportion of cirrhotic patients in those treated for
24 weeks (81.2% of patients treated for this duration, n =
69) than in those treated for 12 weeks (13.3% of patients
treated for 12 weeks, n = 25).
A separate analysis of the 94 cirrhotic patients
included showed a similar evolution. There were no
differences amongst the three groups (p = 0.833).
However, cirrhosis was associated with a decrease in
eGFR (p = 0.036): mean eGFR decrease for cirrhotic
patients was − 5.57 ml/min/1.73m2 (95%CI [(− 8.16)
-(− 2.98)]) vs − 2.28 ml/min/1.73 m2 (95%CI [(− 3.64)
-(− 0.91)] for non-cirrhotic patients.
Table 1 Baseline characteristics of patients according to ARV regimen
Baseline characteristics Non TDF n = 145 Non-boosted TDF n = 78 TDF + Boosted PI n = 50 p
Male, n, (%) 127 (87.6) 67 (85.9) 45 (90.0) 0.78
Mean age ± SD (years) 47 ± 6 47 ± 6 45 ± 6 0.79
Baseline mean creatinine ± SD (mg/dL) 0.84 ± 0.19 0.8 ± 0.13 0.9 ± 0.14 0.05
Baseline mean eGFR ± SD (ml/min/1.73m2) 100.9 ± 16.3 104.1 ± 11.3 98.2 ± 11.8 0.06
Body mass index ± SD (Kg/m2) 23.3 ± 3.9 22.3 ± 4.3 22.8 ± 3.8 0.24
Diabetes, n (%) 5 (3.4) 4 (5.1) 1 (2.0) 0.63
Hypertension, n (%) 21 (14.5) 10 (12.8) 4 (8.0) 0.47
Median CD4+ cell count ± IQ (/mm3) 618 (457–868) 611 (443–762) 506 (279–807) 0.12
VL HIV < 20 cp/mL, n (%) 138 (95.2) 76 (97.4) 44 (88) 0.09
Median stiffness ± IQ (kPa) 9.4 (6.4–15.4) 9.5 (6.9–12.3) 10.5 (7.4–18.2) 0.74
Cirrhosis, n (%) 53 (36.6) 19 (24.4) 22 (44.0) 0.051
Median MELD ± IQ 7 (6–8) 7 (6–7) 7 (7–9) 0.07
Child-Pugh A, n (%) 33 (62.2) 8 (42.1) 9 (40.9) 0.10
SOF/LDV 24 weeks, n (%) 42 (27.2) 24 (30.0) 19 (38.0) 0.50
Ribavirin use, n (%) 28 (18.4) 14 (17.5) 9 (18.0) 0.96
TDF tenofovir, PI protease inhibitor, Non TDF regimens without TDF, Non-boosted TDF regimens with TDF without boosted PI, TDF Boosted PI – regimens with TDF
and boosted PI, SD standard deviation, IQ interquartile range, VL viral load, MELD Model for End-Stage Liver Disease score, SOF sofosbuvir, LDV ledipasvir
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There were six patients whose eGFR decreased to less
than 60 ml/min/1.73m2 during HCV treatment, but, ex-
cept for one patient in the non-TDF group, these de-
creases were transient and were not sustained in the
following assessments. The evolution of these patients is
shown in Table 3.
No patient needed to interrupt HCV treatment due to
renal dysfunction and no patient changed ARV during
HCV treatment. The SVR12 was 98.6, 98.7 and 100% for
the non-TDF, the unboosted TDF and boosted TDF
group, respectively.
Discussion
The SOF/LDV combination pill is an option for the
treatment of HCV genotypes 1 and 4, due to its sim-
ple posology, good tolerability and few DDIs. How-
ever, international guidelines recommend caution (and
frequent renal monitoring) when using these drugs in
HIV coinfected patients receiving TDF and a booster
(either ritonavir or cobicistat) as part of their ARV
regimen due to the increased risk of TDF exposure
and renal toxicity [15, 16].
In our cohort of SOF/LDV treated HCV/HIV
co-infected patients, receiving multiple of ARV thera-
peutic schemes which included regimens without TDF,
with TDF and TDF combined with a ritonavir boosted
PI, we observed a significant decrease in eGFR during
treatment in all study groups. The eGFR decrease was
more pronounced in those patients receiving TDF in
comparison with patients receiving either TDF with a
boosted PI or non-TDF containing regimens, but the
changes were small in all groups and had little clinical
impact. Moreover, we found no statistical differences
amongst the three groups regarding comorbidities. We
found no explanation for the grater decrease in eGFR in
the unboosted TDF group. Treatment duration had
an impact in eGFR decrease, with longer treatment
courses being associated with greater eGFR decrease.
However, the proportion of cirrhotic patients was
much higher in the group of patients treated for
24 weeks (81.2%) and cirrhosis was also associated
with a decrease in eGFR (p = 0.036).
Despite this overall decrease, after treatment comple-
tion eGFR returned to almost baseline values in all
Fig. 1 Evolution of the eGFR during treatment and at SVR12 according to ARV regimen. (eGFR – estimated glomerular filtration rate; D1 – day 1,
beginning of treatment; W2 – week 2 of treatment; W4 – week 4 of treatment; EOT – end of treatment; SVR12 – end of follow up; TDF – tenofovir;
PI – protease inhibitor; Non TDF – regimens without TDF; Non-boosted TDF – regimens with TDF without boosted PI; TDF + Boosted PI – regimens
with TDF and boosted PI)
Table 2 Global Mean eGFR decrease between the baseline and end-of-treatment
Global Mean eGFR Decrease between the baseline and EOT p Confidence Interval
Non TDF n = 152 5.40 ml/min/1.73m2 0.03 95%CI [(−7.44) -(−3.37)]
Non-boosted TDF n = 80 4.31 ml/min/1.73m2 < 0.01 95%CI [(−7.53) -(− 1.09)]
TDF + Boosted PI n = 50 2.02 ml/min/1.73m2 0.01 95%CI [(− 3.84) -(− 0.02)]
TDF tenofovir, PI protease inhibitor, Non TDF regimens without TDF, Non-boosted TDF regimens with TDF without boosted PI, TDF Boosted PI – regimens with TDF
and boosted PI, EOT end of treatment
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groups. We observed the same occurrence in those who
had a longer course of treatment and in cirrhotic pa-
tients. No patient needed to interrupt HCV treatment
due to renal dysfunction and there were no ARV alter-
ations; the SVR12 was above 98% in all groups.
Our results are consistent with the already pub-
lished literature. Bhattacharya and colleagues analysed
a cohort of 996 HCV genotype 1 and HIV co-infected
patients, of which 895 were treated with SOF/LDV ±
RBV; these authors did not find any difference in cre-
atinine change during SOF/LDV treatment in those
receiving either TDF containing ARV schemes (with
or without PI) or those not receiving TDF [18].
Moreover, in line with our results, the median cre-
atinine change was small (0.15 mg/dL in those with-
out TDF, 0.18 mg/dL with TDF and 0.17 mg/dL in
those with TDF + PI) and not different between the
three groups (p = 0.30) [18].
Taramasso et al. evaluated the renal tolerability of the
SOF/LDV in patients participating in the SCOLTA pro-
ject (Surveillance Cohort Long-Term Toxicity Antiretro-
virals), which included 79 HCV/HIV co-infected
patients: 47 taking TDF, 34 a ritonavir boosted PI and 17
TDF + boosted PI [19]. The authors found no statistically
significant variation of eGFR in patients receiving a
boosted PI either in combination with TDF or not [19].
Moreover, they observed that patients receiving
unboosted TDF experienced the highest percentage of
filtration loss (− 5.3 mL/min (SD 15.8)) and that the fre-
quency of eGFR loss > 5% was more frequent in this
group but similarly to our results, there was no differ-
ence between those who took a boosted PI and those
who did not [19].
Despite these reassuring results, Bunnell and col-
leagues published a case of acute tubular necrosis and
acute interstitial nephritis in a HCV/HIV co-infected pa-
tient taking efavirenz/tenofovir/emtricitabine and receiv-
ing HCV treatment with SOF/LDV, that resolved after
discontinuation of TDF and SOF/LDV [20]. Of note, the
patient was also taking other medications that could
contribute to renal injury [20].
The main limitations of our study are its observational
nature and the lack of analysis of other parameters of
renal lesion, namely urine analysis, proteinuria, albumin-
uria, as well as serum and urinary measurements of cal-
cium and phosphate. Moreover, we did not evaluate the
impact of other possible causes of nephrotoxicity. Add-
itionally, data regarding HIV and HCV history is lacking,
due to the lack of informatic records in our hospital.
The ongoing clinical trial NCT02588287 (Effects of
Sofosbuvir/Ledipasvir Treatment on the Pharmacokinet-
ics and Renal Safety of Tenofovir), promoted by the Uni-
versity of Colorado, is likely to shed some more light on
the safety of this combination [21].
Conclusion
We observed a decrease in the mean GFR in all patients
treated with SOF/LDV. This decrease was higher in
those receiving TDF, but the differences amongst the
three groups were small and not statistically significant.
Moreover, the eGFR decrease seems to be reversible
after termination of HCV treatment. Our data, along
with that of other authors [18, 19], reassures clinicians
on the safety of SOF/LDV in combination with TDF
containing regimens, regardless of the concomitant use
of a boosted PI. However, from the authors point of view
and as recommended in guidelines, if TDF is used in pa-
tients who are receiving SOF/LDV, signs of nephrotox-
icity should be carefully monitored [15, 16], especially in
cirrhotic patients.
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